<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003757</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 31/98</org_study_id>
    <secondary_id>SWS-SAKK-31/98</secondary_id>
    <secondary_id>EU-98073</secondary_id>
    <nct_id>NCT00003757</nct_id>
  </id_info>
  <brief_title>Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy</brief_title>
  <official_title>Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy consisting&#xD;
      of rituximab in treating patients with refractory or recurrent hairy cell leukemia following&#xD;
      cladribine therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the rate of complete and partial remission, remission duration, and relapse&#xD;
           free survival after treatment with rituximab in patients with refractory or recurrent&#xD;
           hairy cell leukemia who previously received cladribine.&#xD;
&#xD;
        -  Determine the acute and long term toxicity of rituximab in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive rituximab IV over several hours once a week for 4 weeks.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years and every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-25 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven hairy cell leukemia (HCL)&#xD;
&#xD;
               -  Classic HCL&#xD;
&#xD;
                    -  Hairy cells in the bone marrow and/or peripheral blood which co-express&#xD;
                       CD20/CD25 or CD20/CD11c, and/or which are positive for tartrate resistant&#xD;
                       acid phophatase (TRAP)&#xD;
&#xD;
               -  Prolymphocytic HCL variant&#xD;
&#xD;
                    -  Lymphoid cells in the bone marrow and/or peripheral blood with morphology&#xD;
                       intermediate between typical hairy cells and prolymphocytes, which&#xD;
                       co-express CD20/CD11c but lack CD25 expression, and which are negative for&#xD;
                       TRAP&#xD;
&#xD;
          -  Progressive or recurrent disease after prior treatment with cladribine&#xD;
&#xD;
               -  Greater than 1 month since standard dose cladribine OR&#xD;
&#xD;
               -  Greater than 3 months since low dose cladribine&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.3 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No serious cardiac disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No acute or chronic infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No psychosis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or&#xD;
             basal cell or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No concurrent cytoreductive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert von Rohr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik Hirslanden, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Zenhausern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A; Swiss Group for Clinical Cancer Research (SAKK). Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008 Sep;93(9):1426-8. doi: 10.3324/haematol.11564. Epub 2008 Jul 4. No abstract available.</citation>
    <PMID>18603561</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

